{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-068942","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.251917+00:00","generated_at":"2026-05-31T09:27:36.194812+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"60 Degrees Pharma grants UK right of reference to ARAKODA NDA for SJ733 Phase IIb trial","bullets":["Granted University of Kentucky right of reference to ARAKODA NDA for FDA review of data supporting SJ733 Phase IIb study.","Phase IIb will combine SJ733 (oral ATP4 inhibitor) with tafenoquine for radical cure of Plasmodium vivax malaria.","Study funded by Global Health Innovative Technology Fund; Eisai managing trial material manufacturing and non-clinical studies.","60 Degrees Pharma will supply tafenoquine and placebos as study drugs for the trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-068942","json":"https://secwatch.observer/filing/0001213900-24-068942.json","markdown":"https://secwatch.observer/filing/0001213900-24-068942.md","text":"https://secwatch.observer/filing/0001213900-24-068942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024068942/0001213900-24-068942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024068942/ea0211411-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:27:36.194812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}